Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2026-01-07 00:00:00 ET · period of report 2026-01-05 · accession 0001193125-26-006283 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-07 | 2026-01-05 | NTLA | Lebwohl David | EVP, Chief Medical Off | S - Sale | $9.21 | -11.9K | 121.2K | -9% | -$109.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-05 | S | D | 11,903 | $9.21 | 121,249 | D | — | — | (F2) Includes 1,022 and 1,264 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively. |